ZYNE - Zynerba Pharmaceuticals Inc Stock Price, Fair Value and News

$1.30

Market Closed

ZYNE Stock Valuation Analysis

Valuation

Max Portfolio %

ZYNE Price Action

ZYNE RSI Chart

ZYNE Stock Valuation Analysis

Valuation

Max Portfolio %

ZYNE Valuation

ZYNE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ZYNE Fundamentals

ZYNE Revenue

ZYNE Earnings

ZYNE Profitability

ZYNE Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2018	0	0	0	86.0K
2016	271.3K	255.9K	56.5K	7.3K
2015	677.2K	544.5K	411.7K	278.9K
2014	910.4K	877.0K	843.5K	810.0K
2013	0	0	0	943.9K

Get all data in R, Python etc through our Historical Stock Data APIs

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

CEO	Mr. Armando Anido MBA
WEBSITE	zynerba.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	25